Alvotech will release Q1 2025 financial results on May 7, followed by a conference call on May 8.
Quiver AI Summary
Alvotech, a global biotech company focused on developing and manufacturing biosimilar medicines, announced that it will release its financial results for the first quarter of 2025 on May 7, 2025, after U.S. market close. Following this, a conference call for analysts will be held on May 8, 2025, at 8:00 am EDT to discuss the results and recent business developments, with audio available via a live webcast. The company specializes in biosimilars, having already launched products like Humira® and Stelara® in various markets, with a pipeline that includes nine additional biosimilar candidates targeting multiple health conditions. Alvotech has established numerous partnerships to enhance its commercial reach globally, covering the U.S., Europe, Asia, and parts of South America and Africa. For more information about accessing the conference call or the company itself, interested parties can visit Alvotech's investor website.
Potential Positives
- Alvotech will release its financial results for Q1 2025, indicating active engagement with investors and stakeholders.
- The company will hold a conference call to present financial results and business highlights, promoting transparency and communication with analysts and the public.
- Alvotech's product pipeline includes multiple biosimilar candidates targeting significant health conditions, showcasing its commitment to innovation in the biotechnology sector.
- The establishment of numerous strategic commercial partnerships enhances Alvotech's global reach and market penetration, indicating strong collaboration and support in various regions.
Potential Negatives
- None
FAQ
When will Alvotech release its Q1 2025 financial results?
Alvotech will announce its financial results for Q1 2025 on May 7, 2025, after U.S. markets close.
What time is the conference call for Alvotech's financial results?
The conference call will be held on May 8, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET).
How can I access the Alvotech earnings call webcast?
Access the webcast via Alvotech’s investor website at https://investors.alvotech.com or follow the event link provided.
What biosimilars has Alvotech developed?
Alvotech has developed and marketed biosimilars to Humira® and Stelara® in multiple global markets.
Where can I find more information about Alvotech?
For more information, visit Alvotech’s official website at https://www.alvotech.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ALVO Hedge Fund Activity
We have seen 28 institutional investors add shares of $ALVO stock to their portfolio, and 13 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 839,234 shares (+inf%) to their portfolio in Q4 2024, for an estimated $11,103,065
- OAKTREE CAPITAL MANAGEMENT LP removed 606,322 shares (-23.9%) from their portfolio in Q4 2024, for an estimated $8,021,640
- POINTSTATE CAPITAL LP added 484,826 shares (+64.1%) to their portfolio in Q4 2024, for an estimated $6,414,247
- LEGAL & GENERAL GROUP PLC removed 420,869 shares (-42.2%) from their portfolio in Q4 2024, for an estimated $5,568,096
- SCULPTOR CAPITAL LP removed 338,928 shares (-35.9%) from their portfolio in Q4 2024, for an estimated $4,484,017
- MORGAN STANLEY removed 257,272 shares (-14.8%) from their portfolio in Q4 2024, for an estimated $3,403,708
- MILLENNIUM MANAGEMENT LLC removed 107,172 shares (-84.7%) from their portfolio in Q4 2024, for an estimated $1,417,885
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
REYKJAVIK, Iceland, May 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2025, after U.S. markets close on Wednesday, May 7, 2025. Alvotech will also conduct a conference call with analysts to present the financial results and recent business highlights on Thursday, May 8, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET). Live audio of the conference call will be webcast and available to members of the news media, investors, and the general public.
Information on how to access the webcast or participate by conference call is posted on Alvotech’s investor website https://investors.alvotech.com . Links to access the webcast or sign in number for analysts is found at https://investors.alvotech.com/events/event-details/q1-2025-earnings . The webcast will also be archived and available for replay for 90 days after the event.
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira
®
(adalimumab) and Stelara
®
(ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit
https://www.alvotech.com
. None of the information on the Alvotech website shall be deemed part of this press release.
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
[email protected]
Please visit our investor portal , and our website or follow us on social media on LinkedIn , Facebook , Instagram , and YouTube .
